Abstract
Patients with secondary muscle-invasive bladder cancer (MIBC) treated with neoadjuvant chemotherapy had worse clinical outcomes than patients treated similarly with primary MIBC. These contrasting clinical outcomes may have resulted from differing rates of cisplatin-sensitizing ERCC2 mutations that were enriched in primary MIBC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 231-239 |
| Number of pages | 9 |
| Journal | European urology |
| Volume | 75 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2019 |
Keywords
- Bladder cancer
- ERCC2
- Muscle-invasive bladder cancer
- Neoadjuvant chemotherapy
- Non–muscle-invasive bladder cancer
- Radical cystectomy
ASJC Scopus subject areas
- Urology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy [Figure presented]'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy [Figure presented]. / Pietzak, Eugene J.; Zabor, Emily C.; Bagrodia, Aditya; Armenia, Joshua; Hu, Wenhuo; Zehir, Ahmet; Funt, Samuel; Audenet, Francois; Barron, David; Maamouri, Noelia; Li, Qiang; Teo, Min Yuen; Arcila, Maria E.; Berger, Michael F.; Schultz, Nikolaus; Dalbagni, Guido; Herr, Harry W.; Bajorin, Dean F.; Rosenberg, Jonathan E.; Al-Ahmadie, Hikmat; Bochner, Bernard H.; Solit, David B.; Iyer, Gopa.
In: European urology, Vol. 75, No. 2, 02.2019, p. 231-239.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy [Figure presented]
AU - Pietzak, Eugene J.
AU - Zabor, Emily C.
AU - Bagrodia, Aditya
AU - Armenia, Joshua
AU - Hu, Wenhuo
AU - Zehir, Ahmet
AU - Funt, Samuel
AU - Audenet, Francois
AU - Barron, David
AU - Maamouri, Noelia
AU - Li, Qiang
AU - Teo, Min Yuen
AU - Arcila, Maria E.
AU - Berger, Michael F.
AU - Schultz, Nikolaus
AU - Dalbagni, Guido
AU - Herr, Harry W.
AU - Bajorin, Dean F.
AU - Rosenberg, Jonathan E.
AU - Al-Ahmadie, Hikmat
AU - Bochner, Bernard H.
AU - Solit, David B.
AU - Iyer, Gopa
N1 - Funding Information: Our results suggest that primary and secondary MIBC have disparate clinical outcomes and differential responses to cisplatin-based NAC. Genomic analysis of chemotherapy-naïve specimens reveals that primary MIBC, but not secondary MIBC, is more likely to harbor likely pathogenic ERCC2 mutations predicted to be sensitizing to cisplatin-based chemotherapy. Although cystectomy should ideally be performed before NMIBC progresses to secondary MIBC, the findings of our study suggest that patients with secondary MIBC derive little benefit from current standard cisplatin-based NAC. Further investigation is warranted into whether upfront cystectomy or enrollment into clinical trials of novel agents may be a preferred clinical approach for secondary MIBC. Author contributions : Eugene J. Pietzak had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design : Pietzak, Al-Ahmadie, Bochner, Solit, Iyer. Acquisition of data : Pietzak, Bagrodia, Audenet, Funt, Barron, Maamouri, Li. Analysis and interpretation of data : Pietzak, Zabor, Bagrodia, Armenia, Hu, Zehir, Berger, Schultz, Teo, Dalbagni, Herr, Bajorin, Rosenberg, Al-Ahmadie, Bochner, Solit, Iyer. Drafting of the manuscript : Pietzak, Solit, Iyer. Critical revision of the manuscript for important intellectual content : All authors. Statistical analysis : Zabor. Obtaining funding : Pietzak, Bochner, Solit. Administrative, technical, or material support : Arcila, Berger, Schultz. Supervision : Pietzak, Iyer. Other : None. Financial disclosures: Eugene J. Pietzak certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Pietzak: Scientific Advisory Board: Merck. Berger: Consultant: Roche; Research Support: Illumina. Funt: Research Support: Genentech, AstraZeneca; Stock ownership: Kite Pharma, Urogen Pharma, Allogene Therapeutics, Kronos Bio. Bajorin: Honoraria from the speaker's bureau of Merck; Consultant/advisory board: Merck, Pfizer, Bristol-Myers Squibb, Urogen, Genentech, Eli Lilly. Rosenberg: Stock and Other Ownership Interests: Merck, Illumina; Honoraria: UpToDate, Bristol-Myers Squibb, AstraZeneca, Medscape, Vindico, Peerview, Chugai Pharma; Consulting or Advisory Role: Lilly, Merck, Agensys, Roche/Genentech, Sanofi, AstraZeneca/MedImmune, Bristol-Myers Squibb, EMD Serono, Seattle Genetic, Bayer, Inovio Pharmaceuticals, BioClin Therapeutics, QED Therapeutic, Adicet Bio, Sensei Biotherapeutics; Patents, Royalties, Other Intellectual Property: Predictor of platinum sensitivity; Research Funding: Genentech, Oncogenex, Agensys, Mirati Therapeutics, Novartis, Viralytics, Genentech/Roche, Incyte, Seattle Genetics, Bayer; Travel, Accommodations, Expenses: Genentech/Roche, Bristol-Myers Squibb. Bochner: Chair of data safety monitoring committee: Genentech; Course Instructor: Olympus. Al-Ahmadie: Consultant: Bristol-Myers-Squibb, AstraZeneca, EMD Serono. Solit: Consultant for Pfizer, Loxo Oncology and Illumina. Iyer: Consultant: Bayer. Funding/Support and role of the sponsor : This work was supported by the Sidney Kimmel Center for Prostate and Urologic Cancers, the Michael and Zena Wiener for Therapeutics Program in Bladder Cancer, Pin Down Bladder Cancer, Cycle for Survival, the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, NIH/NCATS Grant Number UL1-TR-002384, and the National Cancer Institute Cancer Center Core Grant Number P30-CA008748. Acknowledgments: The authors thank Jessica Moore and Carol Hoidra for their editorial assistance with this manuscript. Appendix A Publisher Copyright: © 2018 European Association of Urology
PY - 2019/2
Y1 - 2019/2
N2 - Patients with secondary muscle-invasive bladder cancer (MIBC) treated with neoadjuvant chemotherapy had worse clinical outcomes than patients treated similarly with primary MIBC. These contrasting clinical outcomes may have resulted from differing rates of cisplatin-sensitizing ERCC2 mutations that were enriched in primary MIBC.
AB - Patients with secondary muscle-invasive bladder cancer (MIBC) treated with neoadjuvant chemotherapy had worse clinical outcomes than patients treated similarly with primary MIBC. These contrasting clinical outcomes may have resulted from differing rates of cisplatin-sensitizing ERCC2 mutations that were enriched in primary MIBC.
KW - Bladder cancer
KW - ERCC2
KW - Muscle-invasive bladder cancer
KW - Neoadjuvant chemotherapy
KW - Non–muscle-invasive bladder cancer
KW - Radical cystectomy
UR - http://www.scopus.com/inward/record.url?scp=85054135015&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054135015&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2018.09.002
DO - 10.1016/j.eururo.2018.09.002
M3 - Article
C2 - 30290956
AN - SCOPUS:85054135015
VL - 75
SP - 231
EP - 239
JO - European Urology
JF - European Urology
SN - 0302-2838
IS - 2
ER -